Mylan Acquires Butorphanol Tartrate Nasal Spray

Business Wire, August 14, 2001

Business Editors

PITTSBURGH--(BUSINESS WIRE)--Aug. 14, 2001

Mylan Laboratories Inc. (NYSE:MYL) announced today that it has acquired an Abbreviated New Drug Application for the sale of Butorphanol Tartrate Nasal Spray, 10 mg/mL.

Butorphanol is the generic equivalent to Bristol-Myers Squibb Company's Stadol(R) NS, which is indicated for the management of pain when an opoid analgesic is appropriate. Current annual sales for Stadol(R) NS are approximately $82 million. This product will be manufactured by a contract manufacturer and is available for immediate shipment from Mylan's Greensboro, North Carolina distribution center.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. These products are manufactured and sold in a variety of dosage forms including immediate and extended-release oral tablets and capsules and transdermal patches as well as repackaging and marketing multi-source and single-source products in unit dose form. For more information, visit www.mylan.com.